Unleashing the potential of mRNA therapeutics for inherited neurological diseases
Open Access
- 25 April 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Brain
- Vol. 147 (9) , 2934-2945
Abstract
Neurological monogenic loss-of-function diseases are hereditary disorders resulting from gene mutations that decrease or abolish the normal function of the encoded protein. These conditions pose significant therapeutic challenges, which may be resolved through the development of innovative therapeutic strategies. RNA-based technologies, such as mRNA replacement therapy, have emerged as promising and increasingly viable treatments. Notably, mRNA therapy exhibits significant potential as a mutation-agnostic approach that can address virtually any monogenic loss-of-function disease. Therapeutic mRNA carries the information for a healthy copy of the defective protein, bypassing the problem of targeting specific genetic variants. Moreover, unlike conventional gene therapy, mRNA-based drugs are delivered through a simplified process that requires only transfer to the cytoplasm, thereby reducing the mutagenic risks related to DNA integration. Additionally, mRNA therapy exerts a transient effect on target cells, minimizing the risk of long-term unintended consequences. The remarkable success of mRNA technology for developing coronavirus disease 2019 vaccines has rekindled interest in mRNA as a cost-effective method for delivering therapeutic proteins. However, further optimization is required to enhance mRNA delivery, particularly to the CNS, while minimizing adverse drug reactions and toxicity. In this comprehensive review, we delve into past, present and ongoing applications of mRNA therapy for neurological monogenic loss-of-function diseases. We also discuss the promises and potential challenges presented by mRNA therapeutics in this rapidly advancing field. Ultimately, we underscore the full potential of mRNA therapy as a game-changing therapeutic approach for neurological disorders.Keywords
Funding Information
- Ministry of Education and Research
- University of Milan
This publication has 115 references indexed in Scilit:
- mRNA-based therapies: Preclinical and clinical applications2022
- Synthetic modified messenger RNA for therapeutic applicationsActa Biomaterialia, 2021
- Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human PrimatesThe American Journal of Human Genetics, 2019
- Mutations and common variants in the human arginase 1 (ARG1) gene: Impact on patients, diagnostics, and protein structure considerationsHuman Mutation, 2018
- Gene therapy clinical trials worldwide to 2017: An updateThe Journal of Gene Medicine, 2018
- CircRNA: a novel type of biomarker for cancerBreast Cancer, 2017
- Gaucher disease types 1 and 3: Phenotypic characterization of large populations from the ICGG Gaucher RegistryAmerican Journal of Hematology, 2015
- Cell-free protein synthesis: the state of the artBiotechnology Letters, 2012
- mRNA transfection of dendritic cells: Synergistic effect of ARCA mRNA capping with Poly(A) chains in cis and in trans for a high protein expression levelBiochemical and Biophysical Research Communications, 2006
- Structure and function of poly(A) binding proteinsBiochimica et Biophysica Acta (BBA) - Gene Structure and Expression, 2004